Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research HER Pathways 

    • HER1/EGFR 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
      • Overview
      • HER1/EGFR
        • HER1 dysregulation
        • HER1/EGFR evaluation
        • HER1/EGFR and prognosis
        • HER1/EGFR in lung cancer
        • HER1/EGFR in pancreatic cancer
        • HER1/EGFR as a therapeutic target
        • Summary
        • References
      • HER2:HER3 dimer
      • HER2
      • HER3
      • HER4
      • HER pathways slide decks and videos
      • Glossary
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Breast Cancer
    • Ovarian Cancer
  • Molecular Causes of Cancer
    • Evading growth suppressors
  • Biological Pathways
    • HER Signaling
  • Therapeutic Targets
    • HER1
    • HER2
    • HER3
    • HER4
  • Clinical Trials
    • Lung Cancer
    • Pancreatic Cancer
  • Cancer Biomarkers
    • Lung Cancer
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • VEGF in lung cancer
      • Prevalence of VEGF
      • VEGF and prognosis
      • Malignant pleural effusion
      • Survival
      • Summary
      • Evidence of VEGF expression
      • VEGF and disease progression
    • Pancreatic Cancer
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Receptor-Mediated Endocytosis
      • Anti-PDL1 (MPDL3280A)
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
    • Glycoengineered Antibodies
      • HER Signaling
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
    • Non-Antibody Biologics
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
    • Targeted Small Molecules
      • Glossary
      • Slide decks and videos
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
      • Gastric Cancer
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • HER Signaling
      • Anti-PDL1 (MPDL3280A)
      • Inhibition of HER2 dimerization
      • Glossary
      • Slide decks and videos
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
      • Gastric Cancer
HER1 Slide Deck

Slide Deck

View the HER1/EGFR slide deck

View Slide Deck
Share

HER1 Epidermal Growth Factor Receptor (EGFR) Overview

These findings indicate that there is an important role for aberrant EGFR signaling in the development and progression of various human tumors. In addition, they provide a strong rationale for EGFR-TK as a target molecule for the development of new cancer therapies.

— Herbst RS and Bunn PA Jr, Clin Cancer Res, 20031

HER1, also known as the epidermal growth factor receptor (EGFR), drives the development of multiple solid tumor types. This section of ResearchHERPathways.com focuses on HER1/EGFR signaling, how HER1/EGFR is measured, its prognostic value, and its relationship with specific tumor types. Click on the links below to learn more.

  • Dysregulation of HER1/EGFR signaling in cancer
  • Evaluation of HER1/EGFR expression
  • HER1/EGFR as a prognostic factor
  • HER1/EGFR effects in lung cancer
  • HER1/EGFR effects in pancreatic cancer
  • HER1/EGFR as a potential therapeutic target
  • Summary
  • References

View References for this site section

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: HER1 dysregulation »

© 2011 Genentech USA, Inc. All rights reserved